FDA clears updated COVID shots for XFG variant as federal guidance remains stalled
The FDA has approved updated COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi targeting the dominant XFG variant. The shots are approved for adults 65 and older, and younger individuals with underlying health conditions. While manufacturers have begun shipping doses for the 2026-27 season, the absence of a formal CDC recommendation due to legal disputes over the vaccine advisory panel creates uncertainty regarding insurance coverage and pharmacy access in some states.
Key points
- FDA approved updated vaccines from three manufacturers targeting the XFG variant.
- Approval is limited to adults 65+ and younger individuals with underlying conditions.
- Manufacturers confirmed they could produce shots in time for the 2026-27 season.
- CDC has not issued a formal recommendation due to a stalled advisory panel.
- Insurers and pharmacies are navigating coverage and access without federal guidance.
Background
In late August 2026, the FDA initially approved these vaccines for broader adult coverage, targeting strains including LP.8.1 and XFG. Prior to this, a late-summer wave driven by Omicron-related variants had prompted CDC guidance for isolation and masking. Insurers had previously pledged coverage despite federal uncertainty, and medical societies had urged routine vaccination for high-risk groups.
How outlets are covering it
The Guardian and The Washington Post emphasize the regulatory limbo caused by a federal judge blocking Health Secretary Robert F. Kennedy Jr.'s appointments to the CDC vaccine advisory panel. The New York Times highlights that while the FDA approved the shots, legal disputes from past administration actions may complicate access, noting that most Americans can still receive them off-label. The Washington Post notes that while uptake remains low, CDC data shows infections rising in 47 states, though overall activity is lower than previous summers. All sources agree that the lack of a formal CDC recommendation creates uncertainty for insurance coverage and pharmacy availability, though major insurers have pledged to cover the shots.
Why it matters
The approval ensures that high-risk populations have access to updated protection against the dominant XFG variant. However, the lack of a formal CDC recommendation creates a fragmented landscape for access and coverage, potentially leaving some Americans without clear guidance or insurance support for the 2026-27 season.
What to watch
Manufacturers are shipping doses to pharmacies and doctors' offices. Medical societies are expected to issue their own recommendations in early September. The status of the CDC vaccine advisory panel and potential new federal recommendations remain uncertain, which may affect insurance coverage and pharmacy access in some states.
- FDA approves updated Covid-19 vaccines for dominant XFG variant The Guardian
- What to Know About New Covid Vaccines for Fall 2026 The New York Times
- FDA just approved updated covid shots. Here’s what to know as cases rise. The Washington Post
- FDA approves updated COVID-19 vaccines from Pfizer & Moderna, companies say KATU
- FDA approves updated Covid-19 vaccines CNN
Want the full story? Read the original reporting
Read on The Guardian